Get the Stockscreener App
116.38
0.61%
-0.71
Pre-market:
116.36
-0.02
-0.02%
Icon Plc stock is traded at $116.38, with a volume of 643.45K.
It is down -0.61% in the last 24 hours and down -0.10% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$117.09
Open:
$117.09
24h Volume:
643.45K
Relative Volume:
0.35
Market Cap:
$8.89B
Revenue:
$8.10B
Net Income/Loss:
$599.48M
P/E Ratio:
15.73
EPS:
7.3969
Net Cash Flow:
$971.25M
1W Performance:
-6.51%
1M Performance:
-0.10%
6M Performance:
-28.24%
1Y Performance:
-10.93%
1-Day Range:
$115.28
$118.70
1-Week Range:
$115.28
$124.80
52-Week Range:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
116.38 | 8.94B | 8.10B | 599.48M | 971.25M | 7.3969 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
ICON expands US early phase research capabilities with new clinic and outpatient centres - MSN
ICON plc stock (IE0005711209): clinical research specialist after solid Q1 update - AD HOC NEWS
ICLR SEC FilingsICON PLC 10-K, 10-Q, 8-K Forms - Stock Titan
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fra - GuruFocus
Harris Associates L.P. discloses 5.7% stake in ICON plc (ICLR) - Stock Titan
Orbis, Allan Gray file Schedule 13G/A for ICON PLC (ICLR) reporting 0 shares - Stock Titan
Hybrid Clinical Research Job at ICON | Life Science Graduates Must Apply! - BioTecNika
ICON PLC (NASDAQ: ICLR) director logs 5,005-option expiration extension - Stock Titan
ICON PLC (ICLR) director logs mixed transactions on 5,005 stock options - Stock Titan
ICON PLC (ICLR) director reshapes 3,255 stock options in Form 4 - Stock Titan
Wellington entities report 7.74% stake in Icon (ICLR) - Stock Titan
Icon Opens New Clinical Facilities in Move to Expand Early-Phase Capabilities - Moomoo
ICON plc stock (IE0005711209): Expands early-phase research with new Texas clinic - AD HOC NEWS
ICON opens new Texas clinical research unit - BioXconomy
ICON (ICLR) Expands Early Phase Capabilities with New Facilities - GuruFocus
A Look at Icon PLC (ICLR) After 3.7% Decline -- GF Value $241.78 vs Price $117.38 - GuruFocus
Icon announces new Clinical Research Unit in San Antonio, Texas - TipRanks
Icon Expands Early Phase Capabilities - Contract Pharma
ICON's New Texas Hub Aims to Reshape Early Phase Drug Trials - BriefGlance
Hybrid Clinical Research Associate Job at ICON plc | Apply Now - BioTecNika
Templeton Growth Fund, Inc.'s Icon PLC(ICLR) Holding History - GuruFocus
Does ICON (ICLR)ʼs 20‑F Delay Reshape the Narrative Around Its Strong Institutional Ownership Base? - Sahm
A Look at Icon PLC (ICLR) After 4.7% Decline -- GF Value $241.81 vs Price $118.96 - GuruFocus
ICON earnings on deck: Can CRO move past accounting cloud? - Investing.com UK
ICON plc Delays Annual 20-F Amid Restatement - TipRanks
Invesco Ltd. takes 5.1% stake in ICON PLC (ICLR) via 3.88M shares - Stock Titan
FMR LLC discloses 4,174,005.50 shares in ICON PLC (ICLR) on Schedule 13G - Stock Titan
HealthVerity to acquire data platform Symphony Health - MobiHealthNews
Principal Financial Group Inc. Cuts Stock Position in Icon Plc $ICLR - MarketBeat
MSN Money - msn.com
Leerink Partners Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $125 - Moomoo
Icon Plc $ICLR Position Trimmed by Kornitzer Capital Management Inc. KS - MarketBeat
ICON (ICLR) Delays 20-F for Multi-Year Revenue Restatements Is Governance Now the Key Risk? - simplywall.st
Icon PLC | NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F - Moomoo
Is Icon PLC (ICLR) a Bargain After 4.8% Drop? GF Value Says Unde - GuruFocus
Truist Financial Maintains Icon PLC(ICLR.US) With Hold Rating, Announces Target Price $139 - 富途牛牛
ICLR Price Today: Icon Plc Stock Price, Quote & Chart | MEXC - MEXC Exchange
William Blair Maintains Icon PLC(ICLR.US) With Buy Rating - Moomoo
What Just Happened at ICON (ICLR) and Why Did Shares Soar - Kavout
Jennison Associates LLC Makes New $123.54 Million Investment in Icon Plc $ICLR - MarketBeat
Truist reiterates Hold rating on ICON stock, $139 price target - Investing.com UK
Truist reiterates Hold rating on ICON stock, $139 price target By Investing.com - Investing.com India
ICON to Restate 2023–2025 Results After Audit Flags Revenue Recognition Issues - The Globe and Mail
Is It Too Late to Buy Icon PLC (ICLR) After 13.3% Rally? GF Value Says Undervalued - GuruFocus
Icon Clears the Air: Accounting Adjustments Prove Less Severe Than Feared - AD HOC NEWS
ICLR Stock Holds Support As Traders Watch Next Move - StocksToTrade
ICLR Stock Climbs As Support Holds And Value Case Builds - timothysykes.com
ICON Public Limited (ICLR) Shares Surge 13% Following Investigat - GuruFocus
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):